Lignans are low molecular weight polyphenolic compounds with important antitumor and antiviral properties. However, their low ...

Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design, has published a study showcasing the capabilities of its AI platform, GaluxDesign, in de novo antibody design.

Lignans are low molecular weight polyphenolic compounds with important antitumor and antiviral properties. However, their low amounts in medicinal ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Better-than-expected price data can’t quite blunt worries about consumers pulling back, as companies keep scrambling to ...

Ordaos Bio CEO Dave Longo added: “A lot of people claim they are doing truly de novo protein design, but most AI companies claiming ... what your mini protein has to do such as crossing the plant ...

This research marks an important milestone in AI-driven antibody discovery, demonstrating the successful design of antibodies against six distinct therapeutic targets, including a target without an ...

COPENHAGEN, Denmark, March 13, 2025 /PRNewswire/ -- Professor Julia Vorholt's work has changed how we think about plant health ... awarded by the Novo Nordisk Foundation. "Receiving this prize ...